Moderna has unveiled strong topline results from its Phase III study of its respiratory syncytial virus (RSV) mRNA-based vaccine in older people, which suggests it could mount a challenge to frontrunners from GSK and Pfizer.
The company’s prophylactic candidate, mRNA-1345, met the study’s primary endpoint in adults over 60 years, showing vaccine efficacy of 83
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?